Navigation Links
Argos Therapeutics Presents Data Showing Memory T Cell Expansion After Administration of Fully Personalized Immunotherapy Correlates with Overall Survival Benefit in Patients with Metastatic Renal Cell Carcinoma
Date:11/11/2013

ted with patient survival. 

"We believe that these additional findings from our Phase 2 trial support the in vivo mechanism of action of AGS-003," said Charles Nicolette, Argos' chief scientific officer and vice president of research and development, adding, "we also believe this is the first demonstration in a clinical trial that the magnitude of an adaptive immune response following immunotherapy correlates with prolonged survival."  

The Phase 2 clinical trial of AGS-003 in combination with sunitinib enrolled 21 intermediate and poor risk mRCC patients who had a time from diagnosis to initiation of systemic therapeutic treatment of less than one year. Fourteen of these patients were evaluable for immune responses, and median overall survival for these 14 patients was 39.5 months.

Earlier this year, Argos initiated a pivotal Phase 3 clinical trial for AGS-003 ("ADAPT"). The randomized, multicenter, open-label ADAPT clinical trial is designed to examine the potential for AGS-003 plus standard targeted drug therapy to extend OS versus standard therapy alone in newly diagnosed mRCC patients. Argos is using BTSVQ to analyze multi-color flow cytometry data in the ADAPT trial, which will enroll a total of 450 patients in approximately 130 global sites. 

About the Arcelis™ Technology Platform
Arcelis is a fully personalized immunotherapy technology that captures mutated and variant antigens that are specific to each patient's disease. It is designed to overcome immunosuppression by producing a durable memory T cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to a wide range of different cancers and infectious diseases and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies.

The Arcelis process uses only a small tumor or blood sampl
'/>"/>

SOURCE Argos Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
2. Global Aptamers Market Technology Trend Analysis Market Report 2013-2018: Therapeutics, Diagnostics, Biosensors, Biomarker/Drug Discovery & Applications
3. Acquisitions, Project Announcements & Trend Analysis News for Oxygen Biotherapeutics, Glu Mobile, Cisco Systems, Barrick Gold, CVS Caremark
4. Convoy Therapeutics Appoints Clinical Advisory Board
5. Aratana Therapeutics Inc. to Report Third Quarter 2013 Financial Results
6. United Therapeutics Corporation Reports Third Quarter 2013 Financial Results
7. The Zacks Analyst Blog Highlights: Eaton, Baxter International, Bio-Rad Laboratories, INSYS Therapeutics and Boston Scientific
8. Moderna Therapeutics Named to the World Economic Forums Community of "Global Growth Companies"
9. United Therapeutics Corporation to Announce Third Quarter 2013 Financial Results Before Market Open on Tuesday, October 29, 2013
10. PTC Therapeutics Expands Management Team
11. Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... EXpressLO LLC, expert provider of focused ... solutions, has been granted patent number 8,789,826 by the ... incorporating a unique specimen carrier support grid design described ... company patent for EXpressLO LLC awarded to founder and ... complementary patents extend EXpressLO’s portfolio of intellectual property. The ...
(Date:7/28/2014)... using light, developed by researchers at the University of ... considered the realm of science fiction, such as invisibility ... won,t be a reality for quite some time, the ... building blocks a few billionths of a metre across ... flies through them, and works on large chunks all ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 The Workgroup ... authority on the use of health IT to create ... Health Plan Identifier (HPID) Workgroup has developed an ... Health Plan and Payer?” The HPID Workgroup, a part ... with the Centers for Medicare and Medicaid Services (CMS) ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 According ... Transparency Market Research "Regenerative Medicine (Bone and Joint) ... and Tissue Engineering; By Applications - Bone Graft ... Others) - Global Industry Analysis, Size, Share, Growth, ... regenerative medicine (bone and joint) market was valued ...
Breaking Biology Technology:EXpressLO LLC Granted Second U.S. Patent for Innovative Specimen Preparation Methods 2Building 'invisible' materials with light 2WEDI’s HPID Workgroup Announces Release of Issue Brief: “What is the Difference Between a Health Plan and Payer?” 2Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4
... Chicago-based Celsis International, a leading global life sciences company, ... process and will de-list from the London Stock Exchange ... "Celsis has a very strong track record of consistent ... results were not being reflected in our share price," ...
... N.J., Oct. 9 Soligenix, Inc. (Soligenix or the ... announced today that Robert J. Rubin, MD, has been ... has had a distinguished career in the healthcare industry ... as president of the national health policy and management ...
... WA, and VANCOUVER, Oct. 9 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, ... Cormack, president and chief executive officer of OncoGenex, has ... The Year(R). The Ernst & Young Entrepreneur Of The ... entrepreneurs that are building successful, dynamic businesses. , "I ...
Cached Biology Technology:Chicago-Based Celsis International Goes Private 2Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors 2Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors 3Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors 4OncoGenex Pharmaceuticals CEO Named Canada's Pacific Ernst & Young's Entrepreneur Of The Year(R) in the Health Sciences Category 2OncoGenex Pharmaceuticals CEO Named Canada's Pacific Ernst & Young's Entrepreneur Of The Year(R) in the Health Sciences Category 3
(Date:7/28/2014)... John Essigmann and colleagues from the University of Washington had ... they could induce the virus to mutate uncontrollably, they could ... strategy that our immune system uses against many viruses. ... to mutate at an enhanced rate, as expected. But it ... clinical trial reported in 2011. In a new study, however, ...
(Date:7/28/2014)... Eight of the top 10 U.S. cities that have ... public inconveniences as frequent road closures, overwhelmed storm drains ... a new NOAA technical report. , This nuisance flooding, ... three U.S. coasts, between 300 and 925 percent since ... Nuisance Flood Frequency Changes around the United States, also ...
(Date:7/28/2014)... himself the bug hunter, but the target of his ... and identified with special methods and instruments. Benjamin Hause, ... Diagnostic Laboratory at Kansas State University, recently published an ... which is an important find in the United States. ... didn,t know what it was," Hause said. "We used ...
Breaking Biology News(10 mins):Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 2NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 3Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3
... Researchers at the University of Cambridge have discovered a ... within the body, a breakthrough that could lead to ... , Dr. Pietro Mastroeni, Professor Duncan Maskell at ... pioneered the integration of mathematical models with observational data ...
... had narrow, pointed teeth, which were more suited to tearing ... then grind their food? Until recently many researchers have assumed ... their muscular stomach these then acted as a kind of ... correct, as scientists at the universities of Bonn and Tübingen ...
... regulate neuronal signaling in the brain and spinal cord ... mouse with a mutation affecting a neuronal zinc target, ... modulating signaling among the neurons. Significantly, they found the ... as children with the genetic disorder called "startle disease," ...
Cached Biology News:Researchers map spread of pathogens in the human body 2Dinosaurs -- stones did not help with digestion 2Dinosaurs -- stones did not help with digestion 3Zinc plays important role in brain circuitry 2
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Request Info...
Request Info...
Biology Products: